Bon Natural Life (BON) Competitors $1.37 -0.12 (-8.05%) As of 06/18/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BON vs. NMTR, TRVN, PTPI, REVB, NCNA, VIRX, ATXI, BIOR, HEPA, and SYRSShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include 9 Meters Biopharma (NMTR), Trevena (TRVN), Petros Pharmaceuticals (PTPI), Revelation Biosciences (REVB), NuCana (NCNA), Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), Biora Therapeutics (BIOR), Hepion Pharmaceuticals (HEPA), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors 9 Meters Biopharma Trevena Petros Pharmaceuticals Revelation Biosciences NuCana Viracta Therapeutics Avenue Therapeutics Biora Therapeutics Hepion Pharmaceuticals Syros Pharmaceuticals Bon Natural Life (NASDAQ:BON) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking. Do insiders and institutionals have more ownership in BON or NMTR? 0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is BON or NMTR more profitable? Bon Natural Life's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Bon Natural LifeN/A N/A N/A 9 Meters Biopharma N/A -584.97%-159.45% Which has more risk & volatility, BON or NMTR? Bon Natural Life has a beta of -0.47, indicating that its share price is 147% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Which has higher valuation & earnings, BON or NMTR? Bon Natural Life has higher revenue and earnings than 9 Meters Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBon Natural Life$23.84M0.01$400KN/AN/A9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Does the media refer more to BON or NMTR? In the previous week, Bon Natural Life had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Bon Natural Life and 0 mentions for 9 Meters Biopharma. Bon Natural Life's average media sentiment score of 1.05 beat 9 Meters Biopharma's score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the media. Company Overall Sentiment Bon Natural Life Positive 9 Meters Biopharma Neutral Does the MarketBeat Community favor BON or NMTR? 9 Meters Biopharma received 37 more outperform votes than Bon Natural Life when rated by MarketBeat users. Likewise, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 0.00% of users gave Bon Natural Life an outperform vote. CompanyUnderperformOutperformBon Natural LifeOutperform VotesNo VotesUnderperform Votes2100.00% 9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% SummaryBon Natural Life beats 9 Meters Biopharma on 7 of the 11 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$230K$2.14B$8.29B$8.60BDividend YieldN/A4.12%3.34%4.20%P/E RatioN/A14.2619.0619.22Price / Sales0.014.313.43119.81Price / Cash0.1315.6716.5955.99Price / Book0.001.734.456.23Net Income$400K$118.82M$243.10M$249.15M7 Day Performance-10.46%2.79%2.80%0.63%1 Month PerformanceN/A4.29%7.38%2.14%1 Year PerformanceN/A-8.29%6.25%15.81% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural Life0.7472 of 5 stars$1.37-8.1%N/AN/A$230K$23.84M0.00100NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220TRVNTrevena1.7813 of 5 stars$1.02+1.0%$5.00+390.2%-87.1%$978K$443K-0.0240Gap UpPTPIPetros Pharmaceuticals0.2331 of 5 stars$0.03-8.0%N/A-99.7%$966K$5.11M-0.0120Gap DownREVBRevelation Biosciences0.3156 of 5 stars$0.79-1.4%N/A-97.9%$765KN/A0.0010NCNANuCana2.9712 of 5 stars$0.11-24.4%$25.00+21,658.1%-95.9%$698KN/A-0.0130Gap DownHigh Trading VolumeVIRXViracta Therapeutics2.0017 of 5 stars$0.02+4.8%$1.75+9,900.0%-97.5%$696KN/A-0.0220Gap DownATXIAvenue Therapeutics1.7154 of 5 stars$0.21-26.6%N/A-92.9%$663KN/A0.014Gap DownBIORBiora Therapeutics1.7979 of 5 stars$0.15+6.5%$23.00+15,664.2%-97.9%$660K$892K-0.01120HEPAHepion Pharmaceuticals0.6646 of 5 stars$0.07+18.8%N/A-99.8%$645KN/A-0.0220SYRSSyros Pharmaceuticals3.7311 of 5 stars$0.02-7.1%$3.33+14,847.7%-99.5%$598K$386K-0.01120Gap Up Related Companies and Tools Related Companies 9 Meters Biopharma Competitors Trevena Competitors Petros Pharmaceuticals Competitors Revelation Biosciences Competitors NuCana Competitors Viracta Therapeutics Competitors Avenue Therapeutics Competitors Biora Therapeutics Competitors Hepion Pharmaceuticals Competitors Syros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BON) was last updated on 6/20/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BON Stock Free BON Stock Alerts